Goodwin Biotechnology, Inc.  has entered an agreement with Aspyrian Therapeutics, Inc. for the technology transfer, process development, scale-up, and cGMP manufacture of an Antibody Drug Conjugate (ADC) candidate for Phase I trials.    Aspyrian has licensed a new ADC technology platform, Near-infrared Photoimmunotherapy (PIT), from the National Cancer Institute, which allows for efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor. Th...